RxDoctor Payments DataLook up a doctor →

Vanessa Beard-Ely, PA

Physician Assistant · Murray, UTNPI 1730140484

Payments from drug & device makers

$79,830in general payments, 2019–2025

Across 893 payments — averaging $89.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$35K
  • AbbVie$23K
  • Biohaven Pharmaceutical Holding Company Ltd.$9K
  • Pfizer$4K
  • Medtronic$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$1,9202%
  • Speaking & faculty fees$64,35581%
  • Travel & lodging$1,8072%
  • Food & beverage$11,60615%
  • Education$1420%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,830 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$52,637
Medicare patients
238
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate52$279,599
CopaxoneGlatiramer Acetate15$146,054
Nurtec OdtRimegepant Sulfate95$107,450
BotoxOnabotulinumtoxina81$103,046
Emgality PenGalcanezumab-Gnlm110$94,192
XcopriCenobamate75$88,237
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$83,172
Ajovy AutoinjectorFremanezumab-Vfrm91$80,897
Aimovig AutoinjectorErenumab-Aooe100$79,002
AptiomEslicarbazepine Acetate34$74,107
RytaryCarbidopa/Levodopa48$69,943
UbrelvyUbrogepant55$60,607
NuedextaDextromethorphan Hbr/Quinidine17$29,830
GocovriAmantadine Hcl13$24,665
SavellaMilnacipran Hcl33$24,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$321$279,59952 claims
AbbVieBotox, Ubrelvy, Savella, Qulipta, Namzaric$22,838$216,460193 claims
Teva Pharmaceuticals USA, Inc.Copaxone$1,557$146,05415 claims
PfizerNurtec Odt, Dilantin$4,336$109,821107 claims
SK Life Science, Inc.Xcopri$1,274$88,23775 claims
Grifols USA, LLCGamunex-C$16$83,17215 claims
Amneal Pharmaceuticals LLCRytary$59$69,94348 claims
MDD US Operations, LLCGocovri$145$24,66513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →